Edition:
United Kingdom

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

9.89USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$9.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
174,176
52-wk High
$27.19
52-wk Low
$8.94

Ray, Debanjan 

Mr. Debanjan Ray is no longer Chief Financial Officer and Head of Corporate Development of the Company, effective May 15, 2019. Mr. Ray served as our senior vice president of corporate development & strategy from August 2015 to May 2017 and previously as our vice president of business development and alliance management from August 2011 to August 2015. Prior to joining CytomX, he served as vice president of business development at Itero Biopharmaceuticals, Inc. from May 2008 to August 2011. Mr. Ray was associate director, business development at Portola Pharmaceuticals from January 2006 to May 2008. Prior to that, Mr. Ray was an associate in the life sciences venture practice at J.P. Morgan Partners and a business analyst in the healthcare practice at McKinsey & Company. Mr. Ray holds an MBA from The Wharton School, University of Pennsylvania and received his B.S. degree in chemical engineering and biology from the Massachusetts Institute of Technology.

Basic Compensation

Total Annual Compensation, USD 351,126
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,212,000
Fiscal Year Total, USD 1,563,120

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy

3,213,340

Debanjan Ray

1,563,120

Nick Galli

--

Leslie Robbins

--

W. Michael Kavanaugh

1,382,260

Rachel Humphrey

1,539,700
As Of  31 Dec 2017